Robert Coffin
Founder bij REPLIMUNE GROUP, INC.
Vermogen: 15 M $ op 31-03-2024
Profiel
Robert Coffin is the founder of BioVex, Inc. (founded in 1999) and BioVex Group, Inc. (founded in 1999).
He held the title of Chief Technology Officer at BioVex, Inc. in 2009 and Director & Chief Technology Officer at BioVex Group, Inc. from 2009 to 2013.
He is currently the Director & Chief Scientist at Replimune Group, Inc. (founded in 2015).
In addition to his founding positions, Dr. Coffin also held former jobs.
He was the Director & Chief Technology Officer at BioVex Ltd.
from 1999 to 2011.
From 2011 to 2013, he worked as the Vice President-Global Development at Amgen, Inc.Dr. Coffin obtained his doctorate degree from Imperial College London in 1991.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
2.99% | 16-05-2023 | 1 833 336 ( 2.99% ) | 15 M $ | 31-03-2024 |
Actieve functies van Robert Coffin
| Bedrijven | Functie | Begin |
|---|---|---|
| REPLIMUNE GROUP, INC. | Founder | 01-03-2015 |
Eerdere bekende functies van Robert Coffin
| Bedrijven | Functie | Einde |
|---|---|---|
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Founder | 24-01-2013 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2013 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 04-03-2011 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Founder | - |
Opleiding van Robert Coffin
| Imperial College London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
